Chugai Pharmaceutical Co Ltd (OTCPK:CHGCY)
$ 22.58 0.57 (2.59%) Market Cap: 74.31 Bil Enterprise Value: 69.03 Bil PE Ratio: 28.55 PB Ratio: 6.51 GF Score: 85/100

Q2 2020 Chugai Pharmaceutical Co Ltd Earnings Call Transcript

Jul 27, 2020 / 08:00AM GMT
Release Date Price: $24.5 (+1.11%)
Tatsuro Kosaka
Chugai Pharmaceutical Co., Ltd. - Chairman & CEO

I am Tatsuro Kosaka, Chairman and CEO of Chugai Pharmaceutical. Let me review the first half. First, on the financial results of the first half. Please turn to Slide 3.

Despite the outbreak of COVID-19, we have seen a significant increase in revenues and profits in the first half of this year and are on the right track, making steady progress in IBI 21, our midterm business plan. As January-June period results, we achieved record high numbers in revenues, operating profit and net income with revenues up 14.9%, core operating profit up 38.8%, and core EPS up 39.0% year-on-year, respectively. Reasons for this strong performance include steady exports of Actemra and Hemlibra to Roche and Hemlibra-related income. However, domestic sales suffered a negative growth of 2.6% year-on-year. One reason was because our mainstay products, Actemra and Hemlibra, have their NHI drug prices cut in April. The second reason was the impact of the spread of COVID-19 with Tecentriq and Hemlibra, our growth drivers most severely affected.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot